EClinicalMedicine (Oct 2023)

Symptom burden in patients with idiopathic multicentric Castleman disease and its impact on daily life: an international patient and caregiver surveyResearch in context

  • Sudipto Mukherjee,
  • Francis Shupo,
  • Grace Wayi-Wayi,
  • Natasa Zibelnik,
  • Emily Jones,
  • Nicola Mason,
  • Matthew Franklin,
  • John Brazier

Journal volume & issue
Vol. 64
p. 102192

Abstract

Read online

Summary: Background: Idiopathic Multicentric Castleman Disease (iMCD) is a rare inflammatory lymphoproliferative disorder with heterogenous clinical presentations. The symptomatology in iMCD patients remains poorly understood. The aim of this study was to identify the type, frequency and severity of iMCD-related symptoms and the impact of these on the daily lives of iMCD patients and informal-caregivers. Methods: We conducted two bespoke 45-question online surveys for iMCD patients and informal-caregivers of patients recruited from the US, UK, Australia and Canada between April 14 and November 8, 2021. Descriptive data was collected, and a Likert scale was used to quantify the impact of symptoms on various aspects of daily life. Ordinal logistic regression analysis was used to determine associations between age, gender, employment status and symptom burden with aspects of daily life. Findings: Eligible respondents included 51 iMCD patients and 11 informal-caregivers. Patients reported up to 27 unique symptoms, the mean number of symptoms experienced by a patient was 6.7 (range 0–22 symptoms). Most symptoms had a moderate to severe impact on patients' daily lives, with ‘pain/discomfort’, ‘ability to travel’, and ‘sexual functioning’ being the most impacted. iMCD patient characteristics such as being 40 years or older, female, and either disabled or unemployed was significantly associated with adverse impact on several aspects of daily life. Among caregivers, the aspects of daily life that were disproportionately affected was their own social life and freedom, emotional wellbeing, travel/relocation, and work. Interpretation: iMCD patients have widely varied and unappreciated symptomatology. High symptom burden adversely impacts several aspects of patient daily lives as well as their caregivers. Funding: Funding was provided by EUSA Pharma.

Keywords